VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
AUSTIN, Texas, June 25, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, today released a business update video and announced that it will be added to both the Russell 3000® and Russell Microcap® Indexes at the conclusion of the 2020 Russell indexes' annual reconstitution, effective at the close of trading tomorrow, June 26, 2020, based on a preliminary list of additions initially made public on June 5, 2020.
For a business update from Cameron Reynolds, watch this video.
"Inclusion in the Russell Indexes® is an important achievement for Volition. It is a testament to the significant progress we've made as a company over the past few years and we believe that membership will provide further visibility within the financial community and greater liquidity in our shares," stated Cameron Reynolds, Chief Executive Officer of Volition. "We look forward to introducing a wider investor audience to our platform and growth story, and to continuing to execute on our strategy in the second half of the year with several important milestones, including advancing our trials and an expected product launch, that further us on the path toward long-term value creation."
Indexes benchmarked by the FTSE Russell, a leading global index provider, are extensively used by investment managers and institutional investors for index funds as well as a tool to measure active investment strategies. Approximately $9 trillion in assets are benchmarked against the Russell U.S. Indexes.
Membership of the well-known Russell Indexes® brings with it numerous benefits including the automatic insertion into the appropriate growth and value style indexes. This inclusion remains in place for one year. FTSE Russell traditionally determines the membership for its Russell Indexes® by objective, market-capitalization rankings and style attributes.
About FTSE Russell
FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $15 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.
About Volition
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
For more information about Volition, visit Volition's website volition.com or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Batchelor, Volition +44 (0)7557 774620 |
Scott Powell, Volition +1 (646) 650 1351 |
Jen Lewis, Pegasus +44 (0)7809 867943 |
Joseph Green, Edison Advisors +1 (646) 653 7030 |
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements, and include statements regarding the inclusion in the Russell Indexes and the effects thereof, the effectiveness of Volition's blood-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition's actual results, and the timing of events, may differ materially from those indicated in or implied by these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include those identified under the heading "Risk Factors" in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as those identified in documents that Volition files with the Securities and Exchange Commission from time to time. These statements are based on current expectations, estimates and projections based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
NucleosomicsTM is a trademark and/or service mark of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
SOURCE VolitionRx Ltd
Share this article